Evolus

General Information
Business:

We are a medical aesthetics company focused on providing physicians and their patients with expanded choices in aesthetic procedures and treatments. We focus on the self-pay aesthetic market and our first product candidate, PrabotulinumtoxinA (DWP-450), is an injectable 900 kilodalton, or kDa, botulinum toxin type A complex designed to address the needs of the large and growing facial aesthetics market.

Industry: PHARMACEUTICAL PREPARATIONS
Employees: 22
Founded: 2012
Contact Information
Address 17901 Von Karman Avenue, Suite 150 Irvine, CA 92614, US
Phone Number (949) 284-4555
Web Address http://www.evolus.com
View Prospectus: Evolus
Financial Information
Market Cap $283.1mil
Revenues $0 mil (last 12 months)
Net Income $-12.7 mil (last 12 months)
IPO Profile
Symbol EOLS
Exchange NASDAQ
Shares (millions): 5.0
Price range $12.00 - $12.00
Est. $ Volume $60.0 mil
Manager / Joint Managers Cantor/ Mizuho Securities
CO-Managers SunTrust Robinson Humphrey/ JMP Securities
Expected To Trade: 2/8/2018
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change